-

04:12:35 PM

BVXV Stock News

BVXV - Biondvax Pharmaceuticals Ltd

06/07/22 8:41 AM

Nasdaq : BVXV

clinical trialcovid-19low float

BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial

PEI supports BiondVax's plan for first-in-human clinical trial to be conducted in patients as a combined Phase 1/2a, testing both safety and efficacy, thereby shortening BiondVax's clinical development timelines for its first NanoAb product, a COVID-19 therapeutic; PEI is a part of the German

RHEA-AI

very positive

06/01/22 7:10 AM

Nasdaq : BVXV

earningslow float

BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its first

RHEA-AI

very positive

05/19/22 11:17 AM

Nasdaq : BVXV

conferenceslow float

BiondVax to Present at H.C. Wainwright Global Investment Conference

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will

RHEA-AI

neutral

05/12/22 6:30 AM

Nasdaq : BVXV

low float

BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced that Dr. Tamar

RHEA-AI

very positive

05/09/22 6:00 AM

Nasdaq : BVXV

conferenceslow float

BiondVax to Present at this week's Biomed Israel Conference

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will

RHEA-AI

neutral

04/05/22 6:49 AM

Nasdaq : BVXV

conferenceslow float

BiondVax to host a Hebrew-language analyst and investor webinar on April 6th

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that the

RHEA-AI

neutral

03/31/22 4:00 PM

Nasdaq : BVXV

conferenceslow float

BiondVax to host analyst and investor webinar on April 4th

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that the

RHEA-AI

neutral

03/28/22 7:00 AM

Nasdaq : BVXV

earningslow float

BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its fourth

RHEA-AI

very positive

03/24/22 7:05 AM

Nasdaq : BVXV

low float

BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced the signing

RHEA-AI

very positive

03/14/22 8:31 AM

Nasdaq : BVXV

low float

European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New Strategy

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that it had been negotiating with the European Investment Bank (the "EIB") terms of restructuring of its outstanding €24 million loan (the "Loan"). The parties have reached a commercial

RHEA-AI

positive

BVXV Data

Websitewww.biondvax.com
CeoRon Babecoff
Security nameBiondvax Pharmaceuticals Ltd - ADR
Issue typead
Sic code2836
Employees2020
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressWeizmann Science Park
StateNess Ziona
CityPo Box 4143 14 Einstein Street
Zip7403618
CountryIsrael
Phone97289302529

About Biondvax Pharmaceuticals Ltd

BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases. The Company had been developing M 001, a novel flu vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of flu strains. In October 2020, the Company completed a Phase 3 clinical trial of M 001 which failed to meet the trial’s primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets.